Autolus Therapeutics plc (6A3A.F)

3,7000 +0,1000 (+2,78%) Ab 08:08AM CEST. Markt geöffnet.

Autolus Therapeutics plc

The Mediaworks
191 Wood Lane White City
London W12 7FP
United Kingdom
44 20 3829 6230
https://www.autolus.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 463

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Christian Martin Itin Ph.D.	CEO & Director	2,25M	N/A	1964
Dr. Martin Pule M.D., MBBS	Founder, Senior VP & Chief Scientific Officer	N/A	N/A	1972
Mr. Robert F. Dolski	Senior VP & CFO	N/A	N/A	1971
Mr. Christopher Vann	Senior VP & COO	N/A	N/A	1965
Mr. David Brochu	Senior VP & Chief Technical Officer	N/A	N/A	1956
Mr. Alexander Swan	Senior VP & Chief Human Resources Officer	N/A	N/A	1965
Mr. Brent Rice	Senior VP, Chief Commercial Officer & Site Head of US	N/A	N/A	1966
Ms. Olivia Manser	Director of Investor Relations	N/A	N/A	N/A
Mr. Alex Driggs	Senior VP of Legal Affairs & General Counsel and Secretary	N/A	N/A	N/A
Dr. Chris Williams	Senior VP & Chief Business Development Officer	N/A	N/A	1980

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Corporate Governance

Autolus Therapeutics plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.